Rubi Fructus (Rubus coreanus) Inhibits Differentiation to Adipocytes in 3T3-L1 Cells. (30th October 2013)

• Record Type: Journal Article
• Authors: Jeong, Mi-Young; Kim, Hye-Lin; Park, Jinbong; An, Hyo-Jin; Kim, Sung-Hoon; Kim, Su-Jin; So, Hong-Seob; Park, Raekil; Um, Jae-Young; Hong, Seung-Heon
• Other Names: Ko Seong-Gyu Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2013(2013)
• Publication Date: 2013-10-30
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2013/475386
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Rubi Fructus (RF) is known to exert several pharmacological effects including antitumor, antioxidant, and anti-inflammatory activities. However, its antiobesity effect has not been reported yet. This study was focused on the antidifferentiation effect of RF extract on 3T3-L1 preadipocytes. When 3T3-L1 preadipocytes were differentiating into adipocytes, 10–100 μ g/mL of RF was added. Next, the lipid contents were quantified by Oil Red O staining. RF significantly reduced lipid accumulation and downregulated the expression of peroxisome proliferator-activated receptor γ (PPAR γ ), CCAAT0-enhancer-binding proteins α (C/EBP α ), adipocyte fatty acid-binding protein 2 (aP2), resistin, and adiponectin in ways that were concentration dependent. Moreover, RF markedly upregulated liver kinase B1 and AMP-activated protein kinase (AMPK). Interestingly, pretreatment with AMPK α siRNA and RF downregulated the expression of PPAR γ and C/EBP α protein as well as the adipocyte differentiation. Our study shows that RF is capable of inhibiting the differentiation of 3T3-L1 adipocytes through the modulation of PPAR γ, C/EBP α, and AMPK, suggesting that it has a potential for therapeutic application in the treatment or prevention of obesity.